Insider transactions
C. Frank Bennett, who serves as Executive Vice President and Chief Scientific Officer at Ionis Pharmaceuticals, sold 85,089 shares of the company’s common stock on March 3, 2026. The sales were executed across multiple trades with prices ranging from $79.099 to $80.762, producing approximately $6.74 million in gross proceeds.
On the same date Bennett exercised stock options that resulted in the acquisition of 65,089 additional Ionis shares. These option exercises occurred at strike prices of $32.6 and $60.89 and collectively required $3497530 in cash to complete. Following the sales and the option exercises, Bennett’s direct ownership in Ionis stands at 80,554 shares.
Market context
Ionis Pharmaceuticals’ shares have appreciated 123% over the trailing 12 months but have retraced about 5% year-to-date from recent highs. The company’s market capitalization is reported at $12.4 billion, and it remains unprofitable on a trailing twelve-month basis with a loss of $2.38 per share, according to InvestingPro data.
Regulatory and clinical developments
Ionis recently announced that the U.S. Food and Drug Administration accepted its supplemental New Drug Application for olezarsen, a therapy intended for patients with severe hypertriglyceridemia. The agency has set a target action date of June 30, 2026. This regulatory submission follows Phase 3 CORE and CORE2 studies that the company says demonstrated meaningful reductions in triglyceride levels as well as decreases in acute pancreatitis events.
In addition, Ionis is scheduled to present new data for DAWNZERA, an RNA-targeted treatment for hereditary angioedema, at the 2026 American Academy of Allergy, Asthma & Immunology Annual Meeting. The company will feature eight posters based on analyses from the Phase 3 OASIS-HAE and OASISplus studies.
Analyst activity
Several brokerages have adjusted price targets for Ionis in recent notes. Bernstein raised its target to $90, citing a positive outlook for the second half of 2026. Stifel increased its target to $77 based on the company’s pipeline outlook. Morgan Stanley lifted its target to $95, noting strong commercial execution in the fourth quarter of 2025 despite what it described as softer guidance for 2026. These revisions underscore continued analyst interest in the company ahead of upcoming regulatory and commercial milestones.
Implications for investors
The insider sale, option exercise and the company’s ongoing clinical and regulatory activity provide multiple data points for investors evaluating Ionis. The transactions change Bennett’s immediate cash exposure and share count while the company advances programs that may influence its near-term regulatory and commercial trajectory.
Note: Financial metrics cited above are drawn from InvestingPro data referenced in company reporting.